research Priming mobilization of hair follicle stem cells triggers permanent loss of regeneration after alkylating chemotherapy
Chemotherapy causes permanent hair follicle damage by triggering stem cell loss.
Search
for
Sort by
Research
660-690 / 1000+ results 
research 131 Mutational landscape of extramammary Paget disease
The document concludes that ERBB2 mutations are common in extramammary Paget disease and may respond to systemic treatments like cancer immunotherapy.
research Dissecting Cellulitis of the Scalp Successfully Treated with a Combination of Ixekizumab and Tofacitinib
A combination of ixekizumab and tofacitinib successfully treated severe scalp cellulitis, leading to hair regrowth.
research New agents for cancer chemoprevention
Over 30 potential cancer prevention treatments are being tested, with some showing promise in early research.
research Baricitinib: Exploring the Safety Profile for the Treatment of Alopecia Areata
Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.
research Natural Compounds Targeting MAPK, PI3K/Akt, and JAK/STAT Signaling in Papillary Thyroid Cancer
Natural compounds may help treat advanced papillary thyroid cancer by targeting specific molecular pathways.
research A fixed-dose combination of finasteride and tadalafil (Entadfi) for BPH.
Entadfi, a mix of finasteride and tadalafil, is used for BPH.
research 44088 Clinical characteristics, treatment, and outcomes in patients with cutaneous squamous cell carcinoma of the scalp and ear at a reference center in Mexico
Patients with skin cancer on the scalp and ear in Mexico have specific features and results from their treatments.
research Finasteride blocks progesterone synthesis in MA-10 Leydig tumor cells
research Upadacitinib for the Management of Alopecia Totalis and Subtotalis in Pediatric Patients: A Case Series
Upadacitinib may help regrow hair in children with alopecia areata and is generally safe.
research Impact of Previous Alopecia Areata Treatment on Efficacy Responses After 24 and 48 Weeks of Treatment With Ritlecitinib
research Abstract SS02-02: Chemoprevention: Poised for Success
Chemoprevention can significantly lower cancer risks and needs more research and collaboration.